CN104725333A - Preparation method of novel azacycloheptane derivative - Google Patents
Preparation method of novel azacycloheptane derivative Download PDFInfo
- Publication number
- CN104725333A CN104725333A CN201310715025.5A CN201310715025A CN104725333A CN 104725333 A CN104725333 A CN 104725333A CN 201310715025 A CN201310715025 A CN 201310715025A CN 104725333 A CN104725333 A CN 104725333A
- Authority
- CN
- China
- Prior art keywords
- acid
- preparation
- reaction
- formula
- preferred
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/067—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents attached to the same carbon chain, which is not interrupted by carbocyclic rings
Abstract
The invention provides a preparation method of 1-(2-haloethyl)azacycloheptane base ligand and its acid salt. The preparation method is suitable for industrial production. The preparation method is characterized in that 1,6-hexanediol as an initial raw material undergoes three-step reactions to produce the 1-(2-haloethyl)azacycloheptane base ligand and its acid salt. The 1-(2-haloethyl)azacycloheptane base ligand and its acid salt are key intermediates for bazedoxifene synthesis. The preparation method has the advantages of cheap raw material, operation simpleness, mild conditions, simple after-treatment and high yield and is a preparation route suitable for industrialization.
Description
Technical field
The invention belongs to technical field of medicine synthesis, particularly, the present invention relates to the synthesis for the treatment of postmenopausal osteoporosis medicine bazedoxifene acetate key intermediate.
Background technology
Bazedoxifene acetate, English Bazedoxifene Acetate by name, its structural formula is:
Bazedoxifene acetate is developed by Wyeth at first, after transfer Pfizer, be third generation selective estrogen receptor modulators, be mainly used in treat postmenopausal osteoporosis.In April, 2009, commodity were called Conbriza in Italy and Spain's listing, and within 2010, in Japan's listing, commodity are called Viviant, and in October, 2013, commodity were called Duavee in U.S.'s approval listing.
At present, the preparation WAY 140424 of report Measures compare simple possible have following two kinds:
From route map, two kinds of methods all need to use the intermediate of intermediate " 1-(2-chloroethyl) azepan hydrochloride " this key.This intermediate domestic supply producer is fewer and all can not suitability for industrialized production, expensive.The synthetic method of current report is mainly raw material and 1,2-ethylene dichloride generation electrophilic substitution reaction with azepan, is shown below:
The raw material azepan that the method uses is inherently expensive and toxicity is very large, and another kind of raw material 1,2-ethylene dichloride is the kind solvent that toxicity is larger, and it has two reaction site, the improper product being easy to generation two chlorine and all occurring to replace of reaction controlling is not desirable industrialized route in this way.
The exploitation of my company a kind of newly prepare 1-(2-chloroethyl) method of azepan hydrochloride, not only raw materials used low price, and simple to operate, yield is high, whole process does not use the king-sized raw material of toxicity, and the three wastes are few, can not cause too large pressure to environmental protection, it is the industrialized route of a green, environmental protection, greatly can reduce the synthesis cost of bazedoxifene acetate, be conducive to the production domesticization of this medicine, have marketable value and social value.
Summary of the invention
The invention provides a kind of is that 1-(2-chloroethyl prepared by raw material with 1,6-hexylene glycol) method of azepan hydrochloride, not only solve the problem that existing technological process material toxicity is large, cost is high, impurity is many, and good product quality, yield is high.
Technical scheme
1-(2-chloroethyl) preparation method's altogether three-step reaction of azepan hydrochloride:
The first step with 1,6-hexylene glycol and Tosyl chloride be raw material, organic bases as acid binding agent, in methylene dichloride, be obtained by reacting 1,6-bis-tosic acid hexylene glycol ester.
Second step reaction is that raw material generation sulphonate ammonolysis reaction obtains 2-(azepan with 1,6-bis-tosic acid hexylene glycol ester and thanomin)-1-ethanol.
3rd step 2-(azepan)-1-ethanol generation halogenating reaction obtains 1-(2-chloroethyl) azepan hydrochloride or 1-(2-bromotrifluoromethane) azepan hydrobromate
Specific embodiment
The preparation of embodiment one: 1,6-bis-tosic acid hexylene glycol ester
Take 1.77 gram of 1,6-hexylene glycol (15.0mmol) to mix with 30ml anhydrous pyridine, stir and be cooled to 0 DEG C, add 8.58 grams of Tosyl chlorides (45.0mmol).Finish, react 3 hours under room temperature, add 3ml shrend to go out reaction, continue stirring 30 minutes, add methylene dichloride, be added dropwise to 1M hydrochloric acid under stirring and adjust PH=6-7, stir stratification after 30 minutes, dichloromethane layer priority water and saturated brine washing, then dry (anhydrous sodium sulphate), filter, decompression steams methylene dichloride, residue first through column chromatography purification (methylene dichloride/n-hexane/acetone=48:50:2), then obtains 5.12 gram of 1,6-bis-tosic acid hexylene glycol ester (80%) through recrystallization process (methylene dichloride/normal hexane).Mp:77-79 DEG C,
1h NMR (500MHz, CDCl
3) δ 1.25-1.27 (m, 4H), 1.57-1.60 (m, 4H), 2.45 (s; 6H), 3.97 (t, J=6.3Hz, 4H), 7.34 (d; J=8.4Hz, 4H), 7.77 (d, J=8.4Hz, 4H); 13C NMR (125MHz, CDCl3) δ 21.60,21.75,28.26,70.08,127.96,130.00,133.01,144.96; HRMS (ESI) m/z calculated value C20H26O6S2Na [M+Na]
+449.1064; Measured value 449.1068.
Embodiment two: 2-(azepan) preparation of-1-ethanol
A certain amount of 1,6-bis-tosic acid hexylene glycol ester mixes with excessive thanomin and toluene, be heated with stirring to 120 DEG C, react 2 hours, reaction is finished, decompression steams excessive thanomin, methylene dichloride is added, then priority water and saturated brine washing, dry (anhydrous magnesium sulfate), filtration, distillation removing methylene dichloride in residue, residue obtains oily matter 2-(azepan through column chromatography purification (n-hexane/ethyl acetate=98:2))-1-ethanol, yield 90%.
Bp：97℃（14mmHg）
Embodiment three: 1-(2-chloroethyl) preparation of azepan hydrochloride
A certain amount of 2-(azepan)-1-ethanol mixes with methylene dichloride, add the sulfur oxychloride of 5 molar equivalents and the DMF of catalytic amount, be heated with stirring to backflow, react 2 hours, cooling is filtered, filter cake washed with dichloromethane, recrystallisation from isopropanol, vacuum-drying obtains 1-(2-chloroethyl) azepan hydrochloride, yield 85%.Mp:208-209℃。
Claims (5)
1. a 1-(2-haloethyl) azepan alkali body and hydrochlorate thereof
The preparation method of (formula I), is characterized in that with 1,6-hexylene glycol for starting raw material, obtains the compound as formula I through esterification, sulphonate ammonolysis reaction, halogenating reaction.
Wherein X represents halogen atom, as: Cl, Br, I; Y representative can ionize out H
+mineral acid and organic acid, mineral acid is as HCl, HBr, H
2sO
4deng; Organic acid is as HAc, TsOH etc.
2. as claimed in claim 1, esterification is by 1,6-hexylene glycol and SULPHURYL CHLORIDE (RSO
2cl) under acid binding agent exists, reaction generates the intermediate 1 as shown in formula II.
Wherein R represent methyl, ethyl, trifluoromethyl etc. be less than three carbon alkyl or containing the group of phenyl ring, as phenyl, p-methylphenyl etc., preferred p-methylphenyl.Acid binding agent is nitrogenous organic bases, as: triethylamine, pyridine etc.
3. as claimed in claim 1, intermediate 1 and thanomin generation sulphonate ammonolysis reaction obtain the intermediate 2 as shown in formula III.
。
4. as claimed in claim 1, intermediate 2 obtains the compound as shown in formula I through halogenating reaction, and this compound can be alkaline matter, also can be inorganic acid salt or the organic acid salt of alkali body, for the preparation of WAY 140424.
The chlorinating agent that chlorination uses has: PCl
3, PCl
5, SOCl
2, CH
3siCl, HCl etc., preferred SOCl
2; The brominated reagent that bromo-reaction uses has: PBr
3, HBr, Br
2deng, preferred PBr
3; The iodo reagent that iodide reaction uses has: I
2, KI etc., preferred KI.
5. the Y representative as claimed in claim 4, in formula I compound can ionize out H
+mineral acid or organic acid, wherein mineral acid has: hydrochloric acid, Hydrogen bromide, sulfuric acid etc., preferred hydrochloric acid; Organic acid has: HAc, TsOH, CF
3cOOH etc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310715025.5A CN104725333A (en) | 2013-12-20 | 2013-12-20 | Preparation method of novel azacycloheptane derivative |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310715025.5A CN104725333A (en) | 2013-12-20 | 2013-12-20 | Preparation method of novel azacycloheptane derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104725333A true CN104725333A (en) | 2015-06-24 |
Family
ID=53449814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310715025.5A Pending CN104725333A (en) | 2013-12-20 | 2013-12-20 | Preparation method of novel azacycloheptane derivative |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104725333A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109180540A (en) * | 2018-09-20 | 2019-01-11 | 武汉海斯普林科技发展有限公司 | A kind of preparation method and application of highly branched chain dicarboxylic acids ammonium salt |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101784551A (en) * | 2007-06-15 | 2010-07-21 | 万有制药株式会社 | bicycloaniline derivative |
| WO2013090921A1 (en) * | 2011-12-16 | 2013-06-20 | Olema Pharmaceuticals, Inc. | Novel benzopyran compounds, compositions and uses thereof |
-
2013
- 2013-12-20 CN CN201310715025.5A patent/CN104725333A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101784551A (en) * | 2007-06-15 | 2010-07-21 | 万有制药株式会社 | bicycloaniline derivative |
| WO2013090921A1 (en) * | 2011-12-16 | 2013-06-20 | Olema Pharmaceuticals, Inc. | Novel benzopyran compounds, compositions and uses thereof |
Non-Patent Citations (2)
| Title |
|---|
| JIANQUAN FAN 等: "Polymer Micelle with pH-Triggered Hydrophobic−Hydrophilic Transition and De-Cross-Linking Process in the Core and Its Application for Targeted Anticancer Drug Delivery", 《BIOMACROMOLECULES》 * |
| XIAOKE GU 等: "Synthesis and biological evaluation of novel bifendate derivatives bearing 6,7-dihydro-dibenzo[c,e]azepine scaffold as potent P-glycoprotein inhibitors", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109180540A (en) * | 2018-09-20 | 2019-01-11 | 武汉海斯普林科技发展有限公司 | A kind of preparation method and application of highly branched chain dicarboxylic acids ammonium salt |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102230628B1 (en) | Vortioxetine manufacturing process | |
| BRPI0914311A2 (en) | process for preparing abt-263 apoptosis promoter | |
| CN106029658B (en) | The method for preparing Diacloden | |
| CN103601645B (en) | The preparation method of 1-(phenethyl amino) propane-2-alcohol compound or its salt | |
| CN111362939A (en) | Preparation method of palbociclib parent nucleus structure compound | |
| JP5578809B2 (en) | Method for producing 3-methyl-2-thiophenecarboxylic acid | |
| CN103923080A (en) | Method for preparing antithrombotic drug apixaban | |
| KR20120071339A (en) | Process for the production of bendamustine alkyl ester, bendamustine, and derivatives thereof | |
| CN104725333A (en) | Preparation method of novel azacycloheptane derivative | |
| CN105358529A (en) | Novel method for synthesizing key intermediate of apixaban | |
| CN102491886B (en) | Method for synthetizing indanone compound | |
| KR101879181B1 (en) | Precursor of 18f-labeled pet radiopharmaceuticlas and preparation method thereof | |
| CN103588729A (en) | Synthetic method of 1-(biphenyl-4-yl)-2-methyl-2-morpholinopropan-1-one | |
| JP6778588B2 (en) | Method for forming catalyst, amide bond, and method for producing amide compound | |
| CN108409557A (en) | Bu Waxitan new intermediates and its synthetic method and application | |
| JP5099830B2 (en) | Method for producing dibenzoxepin derivative | |
| CN103755657B (en) | A kind of preparation method of Rivaroxaban intermediate | |
| KR101478140B1 (en) | Precursor of １８f-labeled pet radiopharmaceuticlas and preparation method thereof | |
| KR101557702B1 (en) | Method for the preparation of Mitiglinide Calcium Dihydrate | |
| CN102382053B (en) | A kind of method preparing tolvaptan intermediate | |
| CN110590641B (en) | Green preparation method of 3-hydroxyisoindole-1-ketone series compounds | |
| CN104592222A (en) | Preparation method for antiplatelet medicine AZD6482 | |
| CN111170930A (en) | Simple preparation method of 5, 6-dihydropyridine-2 (1H) -ketone derivative | |
| KR101251625B1 (en) | Novel manufacturing method of dutasteride using novel intermediates | |
| KR101170024B1 (en) | Preparation method of azosemide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150624 |
|
| WD01 | Invention patent application deemed withdrawn after publication |